23/06/2026 Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Sanofi’s tolebrutinib approved in the EU for secondary progressive multiple sclerosis without relapses Abbive announced EC approval of risankizumab for the treatment of pediatric patients with oderate to severe plaque psoriasis Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia (Ref) Sanofi announced that the Ministry of Health, Labour and Welfare in Japan had granted marketing and